The European Commission has granted conditional approval to Veklury, the antiviral known as remdesivir.
News & Analysis: Gilead Sciences
Optimism about Gilead’s COVID-19 treatment boosted the shares.
Is an industry leader in treating cystic fibrosis or a company with a potential miracle drug the better buy for investors?
In the U.S., a health insurer insurer should be billed $3,120 per treatment course.
These companies have products, products, and more products to keep revenue flowing.
A key advisory team has given remdesivir a thumbs up, clearing the way to an official green light for its use in Europe.
Gilead will take a chance on privately held Pionyr Immunotherapeutics and its unique cancer treatment candidates.
Sorrento has more momentum right now. But does Gilead's pipeline and dividend make it the better pick?
This version of the investigational antiviral treatment could be administered to COVID-19 patients far more easily, and outside of hospitals.
Gilead’s remdesivir is helping many COVID-19 patients recover, and trials continue to maximize its potential.